EuroPCR 2026: Drug-Coated Balloon (DCB) Strategy Shows Promise in Complex PCI
EuroPCR 2026:
Drug-Coated Balloon (DCB) Strategy Shows Promise in Complex PCI
* A subgroup analysis of the SELUTION De Novo Trial demonstrated that the sirolimus-eluting balloon (SELUTION DCB) is a safe and effective alternative to routine DES implantation in complex PCI.
patients treated with the DCB strategy had fewer adverse events overall.
* The advantage of DCB was mainly due to:
* Fewer heart attacks related to the treated vessel (2.6% vs 7.5%)
* Fewer cardiac deaths (0.7% vs 1.9%)
* The difference between the two groups appeared early after the procedure and remained stable throughout the first year, suggesting that the benefit of the DCB strategy was maintained over time.
Simple Take-Home Message:
In complex PCI, a DCB-based strategy achieved outcomes at least as good as DES and was associated with fewer vessel-related heart attacks and fewer cardiac deaths at 1 year.
Potential Advantages of the DCB Strategy
* Avoids permanent metal implantation.
* Preserves side branches, particularly important in bifurcation lesions.
* May reduce vessel trauma.
* Simplifies treatment in highly complex anatomy.
Important Procedural Points
* Mandatory lesion preparation (predilatation).
* Minimum DCB inflation time: 30 seconds.
* Bailout stenting allowed only for:
* Residual stenosis/recoil > 30%
* High-risk dissection
https://www.tctmd.com/news/
